Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.11.19
Views: 1693

Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA

Prof Maha Hussain speaks to ecancer at ESMO 2019 in Barcelona about data from the PROfound trial comparing the PARP inhibitor olaparib with new hormonal agents in advanced castration resistant prostate cancer.

She reports that in cohort A (patients with BRCA1, BRCA2 or ATM genes) progression free survival was over double in favour of the olaparib and in the overall population of cohort A and cohort B (alterations in other genes involved in DNA repair) there were similar trends.

Prof Hussain believes that this treatment offers a different option for these patients and that it carries a clinical impact. 

Watch the press conference here.

Watch Dr Ignacio Duran's comment here.

Read more about the study here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.


Related videos

follow us

WIN 2020

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation